Literature DB >> 29779902

Molecular genetics and metabolism, special edition: Diagnosis, diagnosis and prognosis of Mucopolysaccharidosis IVA.

Hira Peracha1, Kazuki Sawamoto2, Lauren Averill2, Heidi Kecskemethy2, Mary Theroux3, Mihir Thacker2, Kyoko Nagao4, Christian Pizarro2, William Mackenzie2, Hironori Kobayashi5, Seiji Yamaguchi5, Yasuyuki Suzuki6, Kenji Orii7, Tadao Orii7, Toshiyuki Fukao7, Shunji Tomatsu8.   

Abstract

Mucopolysaccharidosis IVA (MPS IVA, Morquio A syndrome) is an autosomal recessive disorder caused by the deficiency of N-acetylgalactosamine-6-sulfate sulfatase. Deficiency of this enzyme leads to the accumulation of specific glycosaminoglycans (GAGs), chondroitin-6-sulfate (C6S) and keratan sulfate (KS), which are mainly synthesized in the cartilage. Therefore, the substrates are stored primarily in the cartilage and its extracellular matrix (ECM), leading to a direct impact on bone development and successive systemic skeletal spondylepiphyseal dysplasia. The skeletal-related symptoms for MPS IVA include short stature with short neck and trunk, odontoid hypoplasia, spinal cord compression, tracheal obstruction, obstructive airway, pectus carinatum, restrictive lung, kyphoscoliosis, platyspondyly, coxa valga, genu valgum, waddling gait, and laxity of joints. The degree of imbalance of growth in bone and other organs and tissues largely contributes to unique skeletal dysplasia and clinical severity. Diagnosis of MPS IVA needs clinical, radiographic, and laboratory testing to make a complete conclusion. To diagnose MPS IVA, total urinary GAG analysis which has been used is problematic since the values overlap with those in age-matched controls. Currently, urinary and blood KS and C6S, the enzyme activity of GALNS, and GALNS molecular analysis are used for diagnosis and prognosis of clinical phenotype in MPS IVA. MPS IVA can be diagnosed with unique characters although this disorder relates closely to other disorders in some characteristics. In this review article, we comprehensively describe clinical, radiographic, biochemical, and molecular diagnosis and clinical assessment tests for MPS IVA. We also compare MPS IVA to other closely related disorders to differentiate MPS IVA. Overall, imbalance of growth in MPS IVA patients underlies unique skeletal manifestations leading to a critical indicator for diagnosis.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chondroitin-6-sulfate; Keratan sulfate; Mucopolysaccharidosis IVA; N-acetylgalactosamine-6-sulfate; Spondyloepiphyseal dysplasia

Mesh:

Substances:

Year:  2018        PMID: 29779902      PMCID: PMC6175643          DOI: 10.1016/j.ymgme.2018.05.004

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  180 in total

1.  Morquio disease: isolation, characterization and expression of full-length cDNA for human N-acetylgalactosamine-6-sulfate sulfatase.

Authors:  S Tomatsu; S Fukuda; M Masue; K Sukegawa; T Fukao; A Yamagishi; T Hori; H Iwata; T Ogawa; Y Nakashima
Journal:  Biochem Biophys Res Commun       Date:  1991-12-16       Impact factor: 3.575

2.  Practical and reliable enzyme test for the detection of mucopolysaccharidosis IVA (Morquio Syndrome type A) in dried blood samples.

Authors:  Marli V Camelier; Maira G Burin; Jurema De Mari; Taiane A Vieira; Giórgia Marasca; Roberto Giugliani
Journal:  Clin Chim Acta       Date:  2011-06-12       Impact factor: 3.786

Review 3.  Mucopolysaccharidosis type IVA (Morquio A disease): clinical review and current treatment.

Authors:  S Tomatsu; A M Montaño; H Oikawa; M Smith; L Barrera; Y Chinen; M M Thacker; W G Mackenzie; Y Suzuki; T Orii
Journal:  Curr Pharm Biotechnol       Date:  2011-06       Impact factor: 2.837

4.  Molecular analysis of mucopolysaccharidosis IVA (Morquio A) in Spain.

Authors:  Sonia Pajares; Carlos Alcalde; Ma Luz Couce; Mireia Del Toro; Antonio González-Meneses; Encarna Guillén; Mercè Pineda; Guillem Pintos; Laura Gort; Ma José Coll
Journal:  Mol Genet Metab       Date:  2012-03-24       Impact factor: 4.797

Review 5.  Mucopolysaccharidosis VI.

Authors:  Vassili Valayannopoulos; Helen Nicely; Paul Harmatz; Sean Turbeville
Journal:  Orphanet J Rare Dis       Date:  2010-04-12       Impact factor: 4.123

Review 6.  Morquio syndrome: clinical findings in 11 patients with MPS IVA and 2 patients with MPS IVB.

Authors:  W Holzgreve; H Gröbe; K von Figura; H Kresse; H Beck; J F Mattei
Journal:  Hum Genet       Date:  1981       Impact factor: 4.132

7.  MPS screening methods, the Berry spot and acid turbidity tests, cause a high incidence of false-negative results in sanfilippo and morquio syndromes.

Authors:  Chang Chih-Kuang; Lin Shuan-Pei; Lee Shyue-Jye; Wang Tuen-Jen
Journal:  J Clin Lab Anal       Date:  2002       Impact factor: 2.352

8.  Molecular testing of 163 patients with Morquio A (Mucopolysaccharidosis IVA) identifies 39 novel GALNS mutations.

Authors:  A Morrone; K L Tylee; M Al-Sayed; A C Brusius-Facchin; A Caciotti; H J Church; M J Coll; K Davidson; M J Fietz; L Gort; M Hegde; F Kubaski; L Lacerda; F Laranjeira; S Leistner-Segal; S Mooney; S Pajares; L Pollard; I Ribeiro; R Y Wang; N Miller
Journal:  Mol Genet Metab       Date:  2014-03-20       Impact factor: 4.797

Review 9.  Diagnostic and treatment strategies in mucopolysaccharidosis VI.

Authors:  Filippo Vairo; Andressa Federhen; Guilherme Baldo; Mariluce Riegel; Maira Burin; Sandra Leistner-Segal; Roberto Giugliani
Journal:  Appl Clin Genet       Date:  2015-10-30

10.  Orthopedic management of the extremities in patients with Morquio A syndrome.

Authors:  Klane K White; Andrea Jester; C Edward Bache; Paul R Harmatz; Renée Shediac; Mihir M Thacker; William G Mackenzie
Journal:  J Child Orthop       Date:  2014-07-08       Impact factor: 1.548

View more
  20 in total

1.  Effect of enzyme replacement therapy on the growth of patients with Morquio A.

Authors:  Caitlin Doherty; Molly Stapleton; Matthew Piechnik; Robert W Mason; William G Mackenzie; Seiji Yamaguchi; Hironori Kobayashi; Yasuyuki Suzuki; Shunji Tomatsu
Journal:  J Hum Genet       Date:  2019-04-24       Impact factor: 3.172

2.  The GALNS p.P77R variant is a probable Gujarati-Indian founder mutation causing Mucopolysaccharidosis IVA syndrome.

Authors:  Harsh Sheth; Premal Naik; Maulin Shah; Riddhi Bhavsar; Aadhira Nair; Frenny Sheth; Jayesh Sheth
Journal:  BMC Genomics       Date:  2022-06-21       Impact factor: 4.547

3.  Case Report: Diagnosis of Mucopolysaccharidosis Type IVA With Compound Heterozygous Galactosamine-6 Sulfatase Variants and Biopsy of Replaced Femoral Heads.

Authors:  Yiyang Ma; Hao Peng; Fuchou Hsiang; Haoyu Fang; Dajiang Du; Chenyi Jiang; Yehui Wang; Chun Chen; Changqing Zhang; Yun Gao
Journal:  Front Pediatr       Date:  2022-07-04       Impact factor: 3.569

Review 4.  Molecular basis of mucopolysaccharidosis IVA (Morquio A syndrome): A review and classification of GALNS gene variants and reporting of 68 novel variants.

Authors:  Alessandra Zanetti; Francesca D'Avanzo; Moeenaldeen AlSayed; Ana Carolina Brusius-Facchin; Yin-Hsiu Chien; Roberto Giugliani; Emanuela Izzo; David C Kasper; Hsiang-Yu Lin; Shuan-Pei Lin; Laura Pollard; Akashdeep Singh; Rodolfo Tonin; Tim Wood; Amelia Morrone; Rosella Tomanin
Journal:  Hum Mutat       Date:  2021-08-23       Impact factor: 4.700

5.  Liver-Targeted AAV8 Gene Therapy Ameliorates Skeletal and Cardiovascular Pathology in a Mucopolysaccharidosis IVA Murine Model.

Authors:  Kazuki Sawamoto; Subha Karumuthil-Melethil; Shaukat Khan; Molly Stapleton; Joseph T Bruder; Olivier Danos; Shunji Tomatsu
Journal:  Mol Ther Methods Clin Dev       Date:  2020-05-22       Impact factor: 6.698

6.  Normalization of glycosaminoglycan-derived disaccharides detected by tandem mass spectrometry assay for the diagnosis of mucopolysaccharidosis.

Authors:  Hsiang-Yu Lin; Yun-Ting Lo; Tuan-Jen Wang; Sung-Fa Huang; Ru-Yi Tu; Tzu-Lin Chen; Shuan-Pei Lin; Chih-Kuang Chuang
Journal:  Sci Rep       Date:  2019-07-24       Impact factor: 4.379

7.  A Case Report of a Japanese Boy with Morquio A Syndrome: Effects of Enzyme Replacement Therapy Initiated at the Age of 24 Months.

Authors:  Akari Nakamura-Utsunomiya; Toshio Nakamae; Reiko Kagawa; Shuhei Karakawa; Sonoko Sakata; Fumiaki Sakura; Chihiro Tani; Yoshiko Matsubara; Takashi Ishino; Go Tajima; Satoshi Okada
Journal:  Int J Mol Sci       Date:  2020-02-02       Impact factor: 5.923

8.  Morquio-like dysostosis multiplex presenting with neuronopathic features is a distinct GLB1-related phenotype.

Authors:  Sylvia Stockler-Ipsiroglu; Nahid Yazdanpanah; Mojgan Yazdanpanah; Marioara Moisa Popurs; Nataliya Yuskiv; Mara Lúcia Schmitz Ferreira Santos; Chong Ae Kim; Carolina Fischinger Moura de Souza; Charles Marques Lourenço; Carlos Eduardo Steiner; Andressa Federhen; Luciana Giugliani; Débora Maria Bastos Pereira; Luz Elena Durán-Carabali; Roberto Giugliani
Journal:  JIMD Rep       Date:  2021-03-08

9.  Plasma Proteomic Analysis in Morquio A Disease.

Authors:  José V Álvarez; Susana B Bravo; María Pilar Chantada-Vázquez; Sofía Barbosa-Gouveia; Cristóbal Colón; Olalla López-Suarez; Shunji Tomatsu; Francisco J Otero-Espinar; María L Couce
Journal:  Int J Mol Sci       Date:  2021-06-07       Impact factor: 5.923

Review 10.  Hearing Loss in Mucopolysaccharidoses: Current Knowledge and Future Directions.

Authors:  Jeremy Wolfberg; Keerthana Chintalapati; Shunji Tomatsu; Kyoko Nagao
Journal:  Diagnostics (Basel)       Date:  2020-08-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.